Government Tightens Rules For High-Alcohol Medicinal Products To Prevent Misuse

The federal health ministry has introduced stricter regulations for medicinal products containing high levels of ethyl alcohol, effective July 10, 2026. Under the updated guidelines, any formulation containing more than approximately 12 percent ethyl alcohol in quantities exceeding 30 ml will now be classified under Schedule H1 of the Drugs Rules, 1945. This reclassification mandates that such products can only be sold with a valid doctor's prescription and requires manufacturers to obtain specific licenses for their distribution.

The move is primarily aimed at curbing the misuse of medicinal preparations that are sometimes consumed as substitutes for alcohol. By bringing these products under the stringent Schedule H1 category, the government intends to ensure better oversight of their sale and consumption. This regulatory intervention is part of a broader effort to address public health concerns related to substance abuse and to ensure that medicinal products are used strictly for their intended therapeutic purposes under professional medical supervision.

The enforcement of these rules will require pharmacies and healthcare providers to maintain rigorous records of prescriptions and sales. While the policy is designed to protect public health, it also places an additional compliance burden on manufacturers and retailers of such medicinal products. The health ministry expects that these measures will significantly reduce the availability of high-alcohol content medicines for non-medical use, thereby mitigating the risks associated with their misuse across the country.